Shell Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Shell Asset Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-17,595	Closed	-$24K	–	1279
2023 Q1	$24K	Sell	17,595 -58	-0.3%	-$115	﹤0.01%	1226
2022 Q4	$35K	Sell	17,653 -37,869	-68%	-$84.9K	﹤0.01%	1296
2022 Q3	$112K	Sell	55,522 -7,324	-12%	-$20.5K	﹤0.01%	1187
2022 Q2	$200K	Buy	62,846 +107	+0.2%	+$388	0.01%	1123
2022 Q1	$262K	Sell	62,739 -9,283	-13%	-$41.1K	0.01%	1089
2021 Q4	$345K	Buy	72,022 +331	+0.5%	+$1.65K	0.01%	1059
2021 Q3	$383K	Sell	71,691 -3,080	-4%	-$15.5K	0.01%	980
2021 Q2	$383K	Buy	74,771 +4,050	+6%	+$23K	0.01%	1026
2021 Q1	$476K	Buy	70,721 +25,642	+57%	+$142K	0.01%	875
2020 Q4	$206K	Buy	+45,079	New	+$200K	﹤0.01%	1104
2019 Q2	–	Sell	-12,657	Closed	-$179K	–	1226
2019 Q1	$179K	Hold	12,657	–	–	﹤0.01%	1119
2018 Q4	$171K	Sell	12,657 -1,100	-8%	-$19.8K	﹤0.01%	1056
2018 Q3	$305K	Buy	+13,757	New	+$290K	0.01%	1065

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Shell Asset Management's AMRX Position: Q2 2023 in Review

Shell Asset Management sold out of Amneal Pharmaceuticals (AMRX) in Q2 2023, closing a stake of 17,595 shares — an estimated $24K sold.

Shell Asset Management first reported a position in AMRX in Q3 2018 and held it in 13 quarters. The position peaked at $476K in Q1 2021. 128 funds tracked by Wall St. Rank hold AMRX as of Q2 2023.

Shell Asset Management reported no remaining Amneal Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Shell Asset Management sold 17,595 Amneal Pharmaceuticals shares in Q2 2023, an estimated $24K.
Shell Asset Management first reported a position in Amneal Pharmaceuticals in Q3 2018 and held it in 13 quarters.
Shell Asset Management's Amneal Pharmaceuticals position peaked at $476K in Q1 2021.
128 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2023.

Based on Shell Asset Management's 13F filing for Q2 2023, filed 28 Jul 2023.